PRGO vs. JAZZ, CORT, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJ
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Jazz Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals received 335 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.57% of users gave Jazz Pharmaceuticals an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Jazz Pharmaceuticals currently has a consensus target price of $190.92, indicating a potential upside of 70.39%. Perrigo has a consensus target price of $40.67, indicating a potential upside of 50.95%. Given Perrigo's higher possible upside, research analysts plainly believe Jazz Pharmaceuticals is more favorable than Perrigo.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of -0.17%. Perrigo's return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
Jazz Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Perrigo. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 4 mentions for Perrigo. Jazz Pharmaceuticals' average media sentiment score of 1.14 beat Perrigo's score of 0.97 indicating that Perrigo is being referred to more favorably in the news media.
Summary
Jazz Pharmaceuticals beats Perrigo on 14 of the 18 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
